IL-27 Gene Therapy Ameliorates IPEX Syndrome Caused by Germline Mutation of Foxp3 Gene: A Major Role for Induction of IL-10
The Journal of Immunology · 2024
DOI: 10.4049/jimmunol.2400056 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2024. Verfasst von Jin-Qing Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Comprehensive Cancer Center, The Ohio State University, Columbus, OH. Hauptthemen laut MEDLINE: Forkhead Transcription Factors, Interleukin-10, Genetic Therapy, Germ-Line Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NCI NIH HHS, HHS | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Abstract (Originalsprache)
Inactivating mutations of Foxp3, the master regulator of regulatory T cell development and function, lead to immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome in mice and humans. IPEX is a fatal autoimmune disease, with allogeneic stem cell transplant being the only available therapy. In this study, we report that a single dose of adeno-associated virus (AAV)–IL-27 to young mice with naturally occurring Foxp3 mutation (Scurfy mice) substantially ameliorates clinical symptoms, including growth retardation and early fatality. Correspondingly, AAV–IL-27 gene therapy significantly prevented naive T cell activation, as manifested by downregulation of CD62L and upregulation of CD44, and immunopathology typical of IPEX. Because IL-27 is known to induce IL-10, a key effector molecule of regulatory T cells, we evaluated the contribution of IL-10 induction by crossing IL-10–null allele to Scurfy mice. Although IL-10 deficiency does not affect the survival of Scurfy mice, it largely abrogated the therapeutic effect of AAV–IL-27. Our study revealed a major role for IL-10 in AAV–IL-27 gene therapy and demonstrated that IPEX is amenable to gene therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Comprehensive Cancer Center, The Ohio State University, Columbus, OH.
- Department of Dermatology, College of Medicine, University of Iowa, Iowa City, IA.
- Division of Medical Oncology, Department of Internal Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, OH.
- OncoC4, Rockville, MD.
ORCID-Profile: Cho-Hao Lin, Sujit Basu, Xue-Feng Bai
Förderung
- NIAMS NIH HHS
- NCI NIH HHS
- HHS | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- HHS | NIH | National Cancer Institute (NCI)
Zitieren
APA
Liu, J. Q., Jabbari, A., Lin, C. H., Akkanapally, V., Frankel, W. L., Basu, S., He, K., Zheng, P., Liu, Y., & Bai, X. F. (2024). IL-27 Gene Therapy Ameliorates IPEX Syndrome Caused by Germline Mutation of Foxp3 Gene: A Major Role for Induction of IL-10. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2400056
Vancouver
Liu JQ, Jabbari A, Lin CH, Akkanapally V, Frankel WL, Basu S, et al. IL-27 Gene Therapy Ameliorates IPEX Syndrome Caused by Germline Mutation of Foxp3 Gene: A Major Role for Induction of IL-10. The Journal of Immunology. 2024. doi:10.4049/jimmunol.2400056
BibTeX
@article{Liu2024,
author = {Liu, Jin-Qing and Jabbari, Ali and Lin, Cho-Hao and Akkanapally, Venu and Frankel, Wendy L and Basu, Sujit and He, Kai and Zheng, Pan and Liu, Yang and Bai, Xue-Feng},
title = {IL-27 Gene Therapy Ameliorates IPEX Syndrome Caused by Germline Mutation of Foxp3 Gene: A Major Role for Induction of IL-10},
journal = {The Journal of Immunology},
year = {2024},
doi = {10.4049/jimmunol.2400056}
}
EUVIMED